Pharmaceutical

EC approves AstraZeneca’s Imfinzi combo for NSCLC

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC in adults.

Apr 8, 2025 - 06:00
EC approves AstraZeneca’s Imfinzi combo for NSCLC
The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable NSCLC in adults.
Read the original article

Tags:

Previous Article

Obesity drugs won’t be covered by Medicare under 2026 CMS policy

Next Article

BioMed X Launches XBridge Program to Support U.S. Reacsearchers Amid NIH Funding...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opioid addiction market to reach $2.4 billion across 8MM by 2033

Opioid addiction market to reach $2.4 billion across 8M...

Oct 20, 2024

Shionogi awarded $375m from HHS for preventative Covid-19 injectable

Shionogi awarded $375m from HHS for preventative Covid-...

Jan 18, 2025

Avenge Bio secures FDA orphan drug designation for mesothelioma therapy

Avenge Bio secures FDA orphan drug designation for meso...

Jun 17, 2023